A Protein Inhibitor Of Cas9
Patent Status
| Country | Type | Number | Dated | Case |
| United States Of America | Issued Patent | 11,795,208 | 10/24/2023 | 2019-008 |
| United States Of America | Published Application | 20210340199 | 11/04/2021 | 2019-008 |
Brief Description
Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 nucleases, when complexed with a guide RNA, effect genome editing in a sequence-specific manner. RNA-guided Cas9 has proven to be a versatile tool for genome engineering in multiple cell types and organisms. There is a need in the art for additional compositions and methods for controlling genome editing activity of CRISPR/Cas9.
UC Berkeley researchers have discovered a new protein that is able to inhibit the Cas9 protein from
Staphyloccocus aureus (SauCas9). SauCas9 is smaller than the frequently used Cas9 from Streptococcus pyogenes, which has a number of benefits for delivery. The inhibitor is a small protein from a phage and is capable of strongly inhibiting gene editing in human cells.
Suggested uses
- Gene editing
Advantages
- Limiting off-target editing, or other applications where reduced activity or rapid inhibition is desired
Contact
- Terri Sale
- terri.sale@berkeley.edu
- tel: View Phone Number.
Inventors
- Doudna, Jennifer A.
Other Information
Additional Technologies by these Inventors
- COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS
- Genome Editing via LNP-Based Delivery of Efficient and Stable CRISPR-Cas Editors
- Type III CRISPR-Cas System for Robust RNA Knockdown and Imaging in Eukaryotes
- Cas12-mediated DNA Detection Reporter Molecules
- Improved guide RNA and Protein Design for CasX-based Gene Editing Platform
- Cas13a/C2c2 - A Dual Function Programmable RNA Endoribonuclease
- RNA-directed Cleavage and Modification of DNA using CasY (CRISPR-CasY)
- CasX Nickase Designs, Tans Cleavage Designs & Structure
- In Vivo Gene Editing Of Tau Locus Via Liponanoparticle Delivery
- A Dual-RNA Guided CasZ Gene Editing Technology
- CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF (“Cas-VariPhi”)
- Modifications To Cas9 For Passive-Delivery Into Cells
- RNA-directed Cleavage and Modification of DNA using CasX (CRISPR-CasX)
- Compositions and Methods for Genome Editing
- Split-Cas9 For Regulatable Genome Engineering
- NANOPORE MEMBRANE DEVICE AND METHODS OF USE THEREOF
- Methods to Interfere with Prokaryotic and Phage Translation and Noncoding RNA
- CRISPR CASY COMPOSITIONS AND METHODS OF USE
- Single Conjugative Vector for Genome Editing by RNA-guided Transposition
- Improved Cas12a Proteins for Accurate and Efficient Genome Editing
- CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
- Engineered/Variant Hyperactive CRISPR CasPhi Enzymes And Methods Of Use Thereof
- Engineering Cas12a Genome Editors with Minimized Trans-Activity
- Methods Of Use Of Cas12L/CasLambda In Plants
- Type V CRISPR/CAS Effector Proteins for Cleaving ssDNA and Detecting Target DNA
- THERMOSTABLE RNA-GUIDED ENDONUCLEASES AND METHODS OF USE THEREOF (GeoCas9)
- Structure-Guided Methods Of Cas9-Mediated Genome Engineering
- Endoribonucleases For Rna Detection And Analysis
- Efficient Site-Specific Integration Of New Genetic Information Into Human Cells
- CRISPR-Cas Effector Polypeptides and Methods of Use Thereof
- Class 2 CRISPR/Cas COMPOSITIONS AND METHODS OF USE
- Compositions and Methods of Use for Variant Csy4 Endoribonucleases
- Identification Of Sites For Internal Insertions Into Cas9
- Methods and Compositions for Controlling Gene Expression by RNA Processing
